KLOW 80mg
Quad peptide blend: GHK-Cu + BPC-157 + TB-500 + KPV (alpha-MSH tripeptide) co-lyophilized Four published research peptides in a single 80mg vial For in vitro multi-peptide combinatorial research only
For laboratory research use only. Not for human or veterinary consumption. SKU KLOW.
Product details.
What is in the vial
- GHK-Cu: Three amino acids + copper(II) ion. Over 150 published studies. Gene expression modulation affecting ~4,048 human genes. ECM remodeling, copper-dependent enzyme pathways.
- BPC-157: 15 amino acids from human gastric juice. Over 100 published studies. NO pathway modulation, connective tissue models, gastrointestinal research.
- TB-500: 43 amino acids, synthetic thymosin beta-4. LKKTETQ actin-binding motif. Cell migration, wound repair models, cardiac tissue research.
- KPV: The C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH. NF-κB signaling modulation, melanocortin pathway immunomodulatory research.
The KPV component
KPV is the newest addition relative to the Glow triple blend. It brings melanocortin pathway activity into the mix — specifically, research on NF-κB signaling modulation and inflammatory mediator expression in cell culture models. This adds an immunomodulatory dimension that the GHK-Cu/BPC-157/TB-500 combination does not cover on its own.
Specifications
| Total Content | 80mg per vial |
| Format | Co-lyophilized powder |
| Testing | , each component verified |
For laboratory research use only. Not for human or veterinary use.
FDA Disclaimer. All products are for research use only (RUO) as defined by the FDA — not for diagnostic, human, or veterinary use. These products have not been evaluated and have not been approved by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.
Heritage Labs is a chemical supplier providing products strictly for laboratory research, analytical, and in-vitro purposes; it is not a compounding pharmacy or compounding facility under Section 503A, nor an outsourcing facility under Section 503B, of the Federal Food, Drug, and Cosmetic Act.